These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Sykes M; Harty MW; Szot GL; Pearson DA Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457 [TBL] [Abstract][Full Text] [Related]
49. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Ciceri F; Bonini C; Marktel S; Zappone E; Servida P; Bernardi M; Pescarollo A; Bondanza A; Peccatori J; Rossini S; Magnani Z; Salomoni M; Benati C; Ponzoni M; Callegaro L; Corradini P; Bregni M; Traversari C; Bordignon C Blood; 2007 Jun; 109(11):4698-707. PubMed ID: 17327416 [TBL] [Abstract][Full Text] [Related]
50. Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes. Burt RK; Drobyski WR; Traynor AE; Link CJ Bone Marrow Transplant; 1999 Nov; 24(10):1043-51. PubMed ID: 10578153 [TBL] [Abstract][Full Text] [Related]
51. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Chang YJ; Zhao XY; Huang XJ Front Immunol; 2018; 9():3041. PubMed ID: 30619371 [TBL] [Abstract][Full Text] [Related]
52. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285 [TBL] [Abstract][Full Text] [Related]
53. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. Sykes M; Abraham VS; Harty MW; Pearson DA J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257 [TBL] [Abstract][Full Text] [Related]
54. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
55. New developments in allotransplant immunology. Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790 [TBL] [Abstract][Full Text] [Related]
57. Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Hashimoto H; Kitano S; Ueda R; Ito A; Tada K; Fuji S; Yamashita T; Tomura D; Nukaya I; Mineno J; Fukuda T; Mori S; Takaue Y; Heike Y Int J Hematol; 2015 Jul; 102(1):101-10. PubMed ID: 25948083 [TBL] [Abstract][Full Text] [Related]
58. Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. Mailly L; Leboeuf C; Tiberghien P; Baumert T; Robinet E Curr Opin Investig Drugs; 2010 May; 11(5):559-70. PubMed ID: 20419602 [TBL] [Abstract][Full Text] [Related]
59. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia. Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532 [TBL] [Abstract][Full Text] [Related]
60. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]